Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
Vertex Pharmaceuticals(VRTX) stock is priced at $433.07, giving the company a market capitalization of 110B. It carries a P/E multiple of 28.26.
On 2026-03-30, Vertex Pharmaceuticals(VRTX) shares started trading at $450.95, with intraday highs of — and lows of —.
Trading volume for Vertex Pharmaceuticals(VRTX) stock has reached 0, versus its average volume of 1.46M.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $510.77 and a low of $362.50.
Over the past 52 weeks, Vertex Pharmaceuticals(VRTX) stock has traded between a high of $510.77 and a low of $362.50.
VRTX News
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Vertex Pharmaceuticals and keeping the price target at $600.00. Unlock hedge fund-level data...
Earlier in March 2026, analysts including Wells Fargo and Maxim updated their views on Vertex Pharmaceuticals, highlighting the company’s expanding pipeline in...
Key Points Multiple headwinds could bring the bull market to a halt. Stocks positioned to rise even during a market downturn include Berkshire Hathaway, Enbri...
Analyst ratings
78%
of 36 ratingsMore VRTX News
Vertex Pharmaceuticals Inc. (VRTX) announced an update on their ongoing clinical study. Vertex Advances VX-407 Kidney Disease Program With Completed Early Stud...
Maze Therapeutics reported promising Phase II results for its APOL1-mediated kidney disease candidate MZE829. The company plans to move MZE829 into pivotal tes...
Key Points Vertex Pharmaceuticals most important business should still drive sales growth in the 12 months. The biotech could have an improved lineup by next...
Vertex Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite Rating 3/10/2026 Vertex Pharmaceuticals saw an improvement in its IBD SmartSelect Comp...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.